"Designing Growth Strategies is in our DNA"
Region : Global | Latest Update: Sep, 2019 | Published Date: Jun, 2019 | Report ID: FBI100473| Status : Published
The Global Lung Cancer Therapeutics Market was valued at USD 18,327.6 Million in 2018 and is projected to reach USD 48,725.9 Million by 2026, exhibiting a CAGR of 13.0% in the forecast period (2019-2026).
Existing market players operating in the global lung cancer therapeutics market are focusing on constant innovation and up gradation of their product portfolio with new and efficient product offerings for better treatment outcomes for the patients. Lung cancer is among the most commonly occurring cancers in the world and contributes to a significant number of deaths worldwide.
Rise in cancer awareness in both developing and developed nations, and the emergence of new medical diagnostic equipment and advanced therapeutics have increased the number of lung cancer diagnoses, thus propelling the global lung cancer therapeutics market growth. This, coupled with, increasing investments by major players in research and development activities are also boosting the global lung cancer therapeutics market growth. The change in the lung cancer therapeutics market is primarily driven by a greater focus towards the R&D initiatives due to increasing instances of lung cancer.
Get comprehensive study about this report by, request a free sample copy
Some of the other factors which are also contributing to the global lung cancer therapeutics market growth is the increase in the proportion of individuals who smoke and also due to other contributing factors such as exposure to toxins. The introduction of new and sophisticated targeted therapies such as VIZIMPRO by Pfizer Inc. is expected to drive the global lung cancer therapeutics growth in developed as well as emerging countries, during the forecast period 2019-2026.
Increasing R&D advances leading to greater adoption of sophisticated and advanced therapies such as immunotherapy combined with the increasing prevalence of lung cancer is driving the growth of the global market
Increasing adoption and demand for targeted therapies, which is considered to be the foundation of precision medicine due to the increasing R&D initiatives, is one of the most prominent driving factors for the growth of the global lung cancer therapeutics market in 2018. Targeted therapy segment is estimated to have the largest market share among therapy types. The targeted therapy segment accounted for a market share of 51.1% in 2018 and is expected to rise during the forecast period. Increasing focus towards the diagnosis of lung cancer and the subsequent treatment based on the accurate targeting of the tumor or the source of the cancer is also driving the growth in the targeted therapy segment.
The immunotherapy segment is estimated to grow at a faster CAGR during the forecast period. This is attributed to the increasing number of new product launches especially in the immunotherapy segment. Currently, there is increasing adoption of the immunotherapy in the markets in the developed nations due to its higher achievement in terms of the efficient treatment leading to improved patient outcomes, and this is expected to contribute to the growth of the market at higher CAGRs during the forecast period.
Based on the therapy, the global lung cancer therapeutics market segments include targeted therapy (which can be further sub-segmented into bevacizumab, dabrafenib/trametinib, erlotinib hydrochloride, osimertinib, and others), hormonal therapy (which can be further sub-segmented durvalumab, nivolumab, atezolizumab, pembrolizumab), and chemotherapy. The targeted therapy segment dominated the global lung cancer therapeutics market in 2018.
To get details on market share, speak to our analyst
The segment accounted for 51.1% share of the market in 2018. Based on distribution channel, the global market segments include hospital pharmacies, retail pharmacies, online pharmacies, and others. Based on cancer type, the global lung cancer therapeutics market segments include non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC).
North America Lung Cancer Therapeutics Market, 2018
To get geographical overview of this market, request a free sample copy
Growing prevalence of lung cancer and increasing adoption of lung cancer therapeutics expected to result in the highest CAGR in the Asia Pacific
North America generated a lung cancer therapeutics market revenue of US$ 8,093.2 Mn in 2018 and is anticipated to account for a dominant share in the global lung cancer therapeutics market during the forecast period. Growth witnessed in the region is likely to be driven by the increasing adoption of advanced lung cancer therapeutics and rising prevalence and diagnoses of lung cancer. This is especially applicable in instances where the lack of adequate treatment leads to metastasis and subsequently, death. In developed countries, the adoption of advanced immunotherapies is increasing along with the existing therapies of chemotherapy and targeted therapy. The lung cancer therapeutics market is estimated to increase in Europe, due to growing regulatory approvals and the adoption of advanced therapeutics in the region. Whereas, in emerging countries such as India and China, the rise in prevalence of lung cancer is fueling growth in the lung cancer therapeutics market during the forecast period. In countries like China and India, there is an existing dominance of chemotherapy. However, in countries like Japan, there is increased adoption and expenditure towards advanced immunotherapies and targeted therapies. The Latin America and Middle East & Africa, the markets represent future potential for growth due to increasing adoption of advanced therapeutics.
Genentech, Inc. (F. Hoffmann-La Roche Ltd), Bristol Myers Squibb and Merck Sharp & Dohme Corp. to be dominant players in the lung cancer therapeutics market
Genentech, Inc. (F. Hoffmann-La Roche Ltd), emerged as the leading player with the highest lung cancer therapeutics market share in 2018, as the company has a number of product offerings in the targeted therapy and chemotherapy segment, though it trails behind in terms of immunotherapies. The company accounts for the highest revenue shares in the lung cancer therapeutics from regions such as North America and Europe. In addition, other market players are also getting product approvals such as Pfizer, Inc., product offering of VIZIMPRO. Other players operating in the lung cancer therapeutics market are Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly, and Company, Celgene Corporation, AstraZeneca, Pfizer Inc., Sanofi, Novartis AG, Millennium Pharmaceuticals, Inc. (Takeda), Bristol Myers Squibb, Merck Sharp & Dohme Corp., Astellas, etc.
The increasing prevalence of all types of cancers are prevalent in the general population and lung cancer is one of the most common forms of cancer. The increasing prevalence and rising incidence of lung cancer across all demographics and across all the age groups have led to increasing demand for lung cancer therapeutics. According to the American Cancer Society (ACS), about 13% of all new cancer diagnosis are lung cancers.
The report provides qualitative and quantitative insights on the lung cancer therapeutics industry trends and detailed analysis of market size and growth rate for all possible segments in the market. The market segments include therapy, distribution channel, cancer type, and geography. On the basis of therapy, the market segments include targeted therapy, immunotherapy, and chemotherapy. Targeted therapy is further sub-segmented into bevacizumab, dabrafenib/trametinib, erlotinib hydrochloride, osimertinib, and others. Immunotherapy is further sub-segmented into durvalumab, nivolumab, atezolizumab, and pembrolizumab. On the basis of distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others, while the market is classified on the basis of cancer type into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Along with this, the report analysis includes market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of lung cancer therapeutics by key countries, regulatory scenario by key regions, key industry developments and overview of current advances in R&D for lung cancer therapeutics.
To get information on various segments, share your queries with us
By Cancer Type
By Distribution Channel